.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Predict branded drug patent expiration
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

ADENOSCAN Drug Profile

« Back to Dashboard

Which patents cover Adenoscan, and what substitute generic drugs are available?

Adenoscan is a drug marketed by Astellas and is included in one NDA.

The generic ingredient in ADENOSCAN is adenosine. There are twenty-six drug master file entries for this compound. Sixteen suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the adenosine profile page.

Summary for Tradename: ADENOSCAN

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list85
Clinical Trials: see list5
Patent Applications: see list36,920
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ADENOSCAN at DailyMed

Pharmacology for Tradename: ADENOSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
ADENOSCAN
adenosine
SOLUTION;IV (INFUSION)020059-001May 18, 1995DISCNYesNo► Subscribe► Subscribe
Astellas
ADENOSCAN
adenosine
SOLUTION;IV (INFUSION)020059-002May 18, 1995DISCNYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ADENOSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas
ADENOSCAN
adenosine
SOLUTION;IV (INFUSION)020059-001May 18, 19955,070,877► Subscribe
Astellas
ADENOSCAN
adenosine
SOLUTION;IV (INFUSION)020059-001May 18, 19955,731,296► Subscribe
Astellas
ADENOSCAN
adenosine
SOLUTION;IV (INFUSION)020059-002May 18, 19955,731,296► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ADENOSCAN

Drugname Dosage Strength RLD Submissiondate
adenosineInjection3 mg/mL, 20 mL and 30 mL vialsAdenoscan4/16/2005
adenosineInjection3 mg/mL, 20 mL and 30 mL vialsAdenoscan4/18/2005
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc